Abstract
The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Current Medicinal Chemistry
Title: Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Volume: 16 Issue: 17
Author(s): Feng Ru Tang, Henry F. Bradford and Eng-Ang Ling
Affiliation:
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Abstract: The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Export Options
About this article
Cite this article as:
Tang Ru Feng, Bradford F. Henry and Ling Eng-Ang, Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs, Current Medicinal Chemistry 2009; 16 (17) . https://dx.doi.org/10.2174/092986709788612710
DOI https://dx.doi.org/10.2174/092986709788612710 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Focus on Microfluidics and Nanotechnology Approaches for the Ultra Sensitive Detection of MicroRNA
MicroRNA Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review
Recent Advances in Drug Delivery and Formulation Preface
Current Pharmaceutical Design Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?
CNS & Neurological Disorders - Drug Targets Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal
Current Signal Transduction Therapy NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design Genetics of Recurrent Vertigo and Vestibular Disorders
Current Genomics Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Psychotropics and Methadone in Acquired Long QT Syndrome
Current Psychopharmacology Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Clinical Pharmacokinetics of Retigabine/Ezogabine
Current Clinical Pharmacology Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Letters in Drug Design & Discovery Neurogenesis as a New Target for the Development of Antidepressant Drugs
Current Pharmaceutical Design